European Heart Journal

Article	Citations
2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure	6528
2021 ESC Guidelines on cardiovascular disease prevention in clinical practice	3004
2021 ESC/EACTS Guidelines for the management of valvular heart disease	2571
2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension	1433
2022 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death	1059
2021 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy	1007
2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the Internatio	980
2023 ESC Guidelines for the management of acute coronary syndromes	833
SCORE2 risk prediction algorithms: new models to estimate 10-year risk of cardiovascular disease in Europe	599
Diagnosis and treatment of cardiac amyloidosis: a position statement of the ESC Working Group on Myocardial and Pericardial Diseases	570
2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure	481
European Society of Cardiology: cardiovascular disease statistics 2021	466
Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis	452
2023 ESC Guidelines for the management of cardiomyopathies	450
Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement	431
2022 ESC Guidelines on cardiovascular assessment and management of patients undergoing non-cardiac surgery	419
Valve Academic Research Consortium 3: updated endpoint definitions for aortic valve clinical research	416
Triglyceride-rich lipoproteins and their remnants: metabolic insights, role in atherosclerotic cardiovascular disease, and emerging therapeutic strategies—a consensus statement from the European Ather	383
Long COVID: post-acute sequelae of COVID-19 with a cardiovascular focus	366
Pathological features of COVID-19-associated myocardial injury: a multicentre cardiovascular pathology study	363
2023 ESC Guidelines for the management of endocarditis	319
Corrigendum to: 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force	313
2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes	300
Steroidal and non-steroidal mineralocorticoid receptor antagonists in cardiorenal medicine	293
Patterns of myocardial injury in recovered troponin-positive COVID-19 patients assessed by cardiovascular magnetic resonance	284

C-reactive protein and clinical outcomes in patients with COVID-19	272
Defining cardiovascular toxicities of cancer therapies: an International Cardio-Oncology Society (IC-OS) consensus statement	261
SCORE2-OP risk prediction algorithms: estimating incident cardiovascular event risk in older persons in four geographical risk regions	261
The ‘Ten Commandments’ for the 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation	237
Novel antisense therapy targeting microRNA-132 in patients with heart failure: results of a first-in-human Phase 1b randomized, double-blind, placebo-controlled study	214
Corrigendum to: 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure o	212
Left bundle branch area pacing outcomes: the multicentre European MELOS study	212
Prevalence of statin intolerance: a meta-analysis	208
Left ventricular remodelling post-myocardial infarction: pathophysiology, imaging, and novel therapies	191
Eight-year outcomes for patients with aortic valve stenosis at low surgical risk randomized to transcatheter vs. surgical aortic valve replacement	186
Remnant cholesterol predicts cardiovascular disease beyond LDL and ApoB: a primary prevention study	186
The neutrophil–lymphocyte ratio and incident atherosclerotic events: analyses from five contemporary randomized trials	184
Corrigendum to: 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association of Cardio-Thoracic Surgery (EACTS)	180
Management of acute coronary syndromes in patients presenting without persistent ST-segment elevation and coexistent atrial fibrillation – Dual versus triple antithrombotic therapy	173
Isolated tricuspid valve surgery: impact of aetiology and clinical presentation on outcomes	167
Effect of empagliflozin in patients with heart failure across the spectrum of left ventricular ejection fraction	165
Cardiovascular health after menopause transition, pregnancy disorders, and other gynaecologic conditions: a consensus document from European cardiologists, gynaecologists, and endocrinologists	163
Coronary flow reserve and cardiovascular outcomes: a systematic review and meta-analysis	157
Heart failure drug treatment: the fantastic four	154
Genome-wide analysis identifies novel susceptibility loci for myocardial infarction	148
Corrigendum to: 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association of Cardio-Thoracic Surgery (EACTS)	147
Association between adiposity and cardiovascular outcomes: an umbrella review and meta-analysis of observational and Mendelian randomization studies	147
Propionate attenuates atherosclerosis by immune-dependent regulation of intestinal cholesterol metabolism	146
The physical activity paradox in cardiovascular disease and all-cause mortality: the contemporary Copenhagen General Population Study with 104 046 adults	145
TRI-SCORE: a new risk score for in-hospital mortality prediction after isolated tricuspid valve surgery	144
Empagliflozin in acute myocardial infarction: the EMMY trial	143
Lifestyle, cardiometabolic disease, and multimorbidity in a prospective Chinese study	143
Joint exposure to various ambient air pollutants and incident heart failure: a prospective analysis in UK Biobank	143
Efficacy and safety of low-dose colchicine in patients with coronary disease: a systematic review and meta-analysis of randomized trials	142
The ESC Clinical Practice Guidelines for the Management of Adult Congenital Heart Disease 2020	140
Thin-cap fibroatheroma predicts clinical events in diabetic patients with normal fractional flow reserve: the COMBINE OCT–FFR trial	139
Causal associations of short and long sleep durations with 12 cardiovascular diseases: linear and nonlinear Mendelian randomization analyses in UK Biobank	139
Associations between gut microbiota, faecal short-chain fatty acids, and blood pressure across ethnic groups: the HELIUS study	136
Combining loop with thiazide diuretics for decompensated heart failure: the CLOROTIC trial	135
AV junction ablation and cardiac resynchronization for patients with permanent atrial fibrillation and narrow QRS: the APAF-CRT mortality trial	132
Effect of dapagliflozin on ventricular arrhythmias, resuscitated cardiac arrest, or sudden death in DAPA-HF	131
The European bifurcation club Left Main Coronary Stent study: a randomized comparison of stepwise provisional vs. systematic dual stenting strategies (EBC MAIN)	131
Lipoprotein(a) lowering by alirocumab reduces the total burden of cardiovascular events independent of low-density lipoprotein cholesterol lowering: ODYSSEY OUTCOMES trial	130
Effect of empagliflozin on exercise ability and symptoms in heart failure patients with reduced and preserved ejection fraction, with and without type 2 diabetes	129
Application of artificial intelligence to the electrocardiogram	128
Bariatric surgery and cardiovascular disease: a systematic review and meta-analysis	126
Multi-organ assessment in mainly non-hospitalized individuals after SARS-CoV-2 infection: The Hamburg City Health Study COVID programme	123
Non-linear Mendelian randomization analyses support a role for vitamin D deficiency in cardiovascular disease risk	121
Empagliflozin and health-related quality of life outcomes in patients with heart failure with reduced ejection fraction: the EMPEROR-Reduced trial	120
Electrocardiogram screening for aortic valve stenosis using artificial intelligence	119
Elevated remnant cholesterol increases the risk of peripheral artery disease, myocardial infarction, and ischaemic stroke: a cohort-based study	113
Efficacy of a digital therapeutics system in the management of essential hypertension: the HERB-DH1 pivotal trial	112
Salt and cardiovascular disease: insufficient evidence to recommend low sodium intake	111
Mendelian randomization for cardiovascular diseases: principles and applications	111
Colchicine and the heart	109

Ticagrelor alone vs. ticagrelor plus aspirin following percutaneous coronary intervention in patients with non-ST-segment elevation acute coronary syndromes: TWILIGHT-ACS	104
Short dual antiplatelet therapy followed by P2Y12 inhibitor monotherapy vs. prolonged dual antiplatelet therapy after percutaneous coronary intervention with second-generation drug-eluting stents: a s	104
Exercise-based cardiac rehabilitation for coronary heart disease: a meta-analysis	104
The risk of cardiac events in patients receiving immune checkpoint inhibitors: a nationwide Danish study	103
Inclisiran and cardiovascular events: a patient-level analysis of phase III trials	103
Combination lipid-lowering therapy as first-line strategy in very high-risk patients	102
Heart failure with preserved ejection fraction in patients with normal natriuretic peptide levels is associated with increased morbidity and mortality	102
Systematic, early rhythm control strategy for atrial fibrillation in patients with or without symptoms: the EAST-AFNET 4 trial	102
Validation of high bleeding risk criteria and definition as proposed by the academic research consortium for high bleeding risk	100
Influence of neprilysin inhibition on the efficacy and safety of empagliflozin in patients with chronic heart failure and a reduced ejection fraction: the EMPEROR-Reduced trial	99
Low-density lipoprotein cholesterol reduction and statin intensity in myocardial infarction patients and major adverse outcomes: a Swedish nationwide cohort study	99
Comparative effects of guided vs. potent P2Y12 inhibitor therapy in acute coronary syndrome: a network meta-analysis of 61 898 patients from 15 randomized trials	99
Apixaban vs. standard of care after transcatheter aortic valve implantation: the ATLANTIS trial	97
Frailty and cardiovascular outcomes in the National Health and Aging Trends Study	97
Long-term night shift work is associated with the risk of atrial fibrillation and coronary heart disease	96
Clinical characteristics and prognosis of patients with microvascular angina: an international and prospective cohort study by the Coronary Vasomotor Disorders International Study (COVADIS) Group	96
Post-stenting fractional flow reserve vs coronary angiography for optimization of percutaneous coronary intervention (TARGET-FFR)	96
Apolipoprotein C-III reduction in subjects with moderate hypertriglyceridaemia and at high cardiovascular risk	96
Optimal follow-up after acute pulmonary embolism: a position paper of the European Society of Cardiology Working Group on Pulmonary Circulation and Right Ventricular Function, in collaboration with th	95
Angiotensin-converting enzyme 2 (ACE2) levels in relation to risk factors for COVID-19 in two large cohorts of patients with atrial fibrillation	95
Clonal haematopoiesis in chronic ischaemic heart failure: prognostic role of clone size for DNMT3A- and TET2-driver gene mutations	95
Patiromer for the management of hyperkalemia in heart failure with reduced ejection fraction: the DIAMOND trial	94
Impact of empagliflozin on decongestion in acute heart failure: the EMPULSE trial	94
Antiplatelet therapy in patients with conservatively managed spontaneous coronary artery dissection from the multicentre DISCO registry	93
The win ratio approach for composite endpoints: practical guidance based on previous experience	93
The effect of spironolactone on cardiovascular function and markers of fibrosis in people at increased risk of developing heart failure: the heart ‘OMics’ in AGEing (HOMAGE) randomized clinical trial	93
ESC guidance for the diagnosis and management of cardiovascular disease during the COVID-19 pandemic: part 2—care pathways, treatment, and follow-up	92
Pathophysiologic importance of visceral adipose tissue in women with heart failure and preserved ejection fraction	92
Sacubitril–valsartan as a treatment for apparent resistant hypertension in patients with heart failure and preserved ejection fraction	91
Pulmonary embolism in patients with COVID-19: incidence, risk factors, clinical characteristics, and outcome	91
Calcific aortic valve disease: from molecular and cellular mechanisms to medical therapy	91
Cardiac mortality in patients randomised to elective coronary revascularisation plus medical therapy or medical therapy alone: a systematic review and meta-analysis	90
Targeting early stages of cardiotoxicity from anti-PD1 immune checkpoint inhibitor therapy	90
Alcohol consumption, cardiac biomarkers, and risk of atrial fibrillation and adverse outcomes	90
Cardiac arrest in COVID-19: characteristics and outcomes of in- and out-of-hospital cardiac arrest. A report from the Swedish Registry for Cardiopulmonary Resuscitation	89
Effects of canagliflozin on serum potassium in people with diabetes and chronic kidney disease: the CREDENCE trial	89
The management of secondary mitral regurgitation in patients with heart failure: a joint position statement from the Heart Failure Association (HFA), European Association of Cardiovascular Imaging (EA	88
Chronic thromboembolic pulmonary hypertension and impairment after pulmonary embolism: the FOCUS study	87
Effect of empagliflozin on circulating proteomics in heart failure: mechanistic insights into the EMPEROR programme	87
Sex differences in arterial hypertension	87
Management of antithrombotic therapy in patients undergoing transcatheter aortic valve implantation: a consensus document of the ESC Working Group on Thrombosis and the European Association of Percuta	86
Cardiovascular immunotoxicities associated with immune checkpoint inhibitors: a safety meta-analysis	86
CDR132L improves systolic and diastolic function in a large animal model of chronic heart failure	86
Antithrombotic therapies in aortic and peripheral arterial diseases in 2021: a consensus document from the ESC working group on aorta and peripheral vascular diseases, the ESC working group on thrombo	85
Women who experience a myocardial infarction at a young age have worse outcomes compared with men: the Mass General Brigham YOUNG-MI registry	84
Less dementia after catheter ablation for atrial fibrillation: a nationwide cohort study	84
Assessment and pathophysiology of microvascular disease: recent progress and clinical implications	84
Targeting the CCL2–CCR2 axis for atheroprotection	83
Directly measured vs. calculated remnant cholesterol identifies additional overlooked individuals in the general population at higher risk of myocardial infarction	83
Effects of dapagliflozin on mortality in patients with chronic kidney disease: a pre-specified analysis from the DAPA-CKD randomized controlled trial	83
Incidence, risk factors, and mortality of atrial fibrillation in breast cancer: a SEER-Medicare analysis	82
Fractional flow reserve derived from computed tomography coronary angiography in the assessment and management of stable chest pain: the FORECAST randomized trial	81
High-density lipoprotein revisited: biological functions and clinical relevance	80
The JAK–STAT pathway: an emerging target for cardiovascular disease in rheumatoid arthritis and myeloproliferative neoplasms	80
Leadless vs. transvenous single-chamber ventricular pacing in the Micra CED study: 2-year follow-up	80
Heart failure with preserved ejection fraction in humans and mice: embracing clinical complexity in mouse models	79
A polygenic risk score improves risk stratification of coronary artery disease: a large-scale prospective Chinese cohort study	79
Prognostically relevant periprocedural myocardial injury and infarction associated with percutaneous coronary interventions: a Consensus Document of the ESC Working Group on Cellular Biology of the He	79
2023 Update on European Atherosclerosis Society Consensus Statement on Homozygous Familial Hypercholesterolaemia: new treatments and clinical guidance	79
Untargeted metabolomics identifies succinate as a biomarker and therapeutic target in aortic aneurysm and dissection	78
The “ten commandments” for the 2021 ESC/EACTS Guidelines on valvular heart disease	78
The dawn of a new era of targeted lipid-lowering therapies	77
The novel cystatin C, lactate, interleukin-6, and N-terminal pro-B-type natriuretic peptide (CLIP)-based mortality risk score in cardiogenic shock after acute myocardial infarction	77
Procedural myocardial injury, infarction and mortality in patients undergoing elective PCI: a pooled analysis of patient-level data	77
Imaging predictors of response to cardiac resynchronization therapy: left ventricular work asymmetry by echocardiography and septal viability by cardiac magnetic resonance	77
Triaging acute pulmonary embolism for home treatment by Hestia or simplified PESI criteria: the HOME-PE randomized trial	76
Clinical characteristics and outcomes in childhood-onset hypertrophic cardiomyopathy	75
Road traffic noise and cardiovascular disease risk factors in UK Biobank	75
The ‘10 commandments’ for the 2021 ESC guidelines on cardiac pacing and cardiac resynchronization therapy	75
Stress-associated neurobiological activity associates with the risk for and timing of subsequent Takotsubo syndrome	74
Relative risk of arterial and venous thromboembolism in persons with cancer vs. persons without cancer—a nationwide analysis	74
SCORE2-Diabetes: 10-year cardiovascular risk estimation in type 2 diabetes in Europe	73
Midlife blood pressure is associated with the severity of white matter hyperintensities: analysis of the UK Biobank cohort study	72
Differential immunological signature at the culprit site distinguishes acute coronary syndrome with intact from acute coronary syndrome with ruptured fibrous cap: results from the prospective translat	72
The effect of intravenous ferric carboxymaltose on health-related quality of life in iron-deficient patients with acute heart failure: the results of the AFFIRM-AHF study	72
Iron deficiency and cardiovascular disease	71
Sex differences in outcomes after coronary artery bypass grafting: a pooled analysis of individual patient data	71
Evaluation of gene validity for CPVT and short QT syndrome in sudden arrhythmic death	71
Effects of canagliflozin on human myocardial redox signalling: clinical implications	71
STING, a cytosolic DNA sensor, plays a critical role in atherogenesis: a link between innate immunity and chronic inflammation caused by lifestyle-related diseases	70

Genetically determined NLRP3 inflammasome activation associates with systemic inflammation and cardiovascular mortality	70
Cardiac pacing in severe recurrent reflex syncope and tilt-induced asystole	70
Anthropometric measures and adverse outcomes in heart failure with reduced ejection fraction: revisiting the obesity paradox	70
Lectin-like oxidized low-density lipoprotein receptor-1 (LOX-1): a crucial driver of atherosclerotic cardiovascular disease	69
Critical appraisal of artificial intelligence-based prediction models for cardiovascular disease	69
European Society of Cardiology guidance for the diagnosis and management of cardiovascular disease during the COVID-19 pandemic: part 1—epidemiology, pathophysiology, and diagnosis	69
Outdoor light at night and risk of coronary heart disease among older adults: a prospective cohort study	69
Pulmonary vascular disease in pulmonary hypertension due to left heart disease: pathophysiologic implications	68
Metoprolol exerts a non-class effect against ischaemia–reperfusion injury by abrogating exacerbated inflammation	68
Heart healthy cities: genetics loads the gun but the environment pulls the trigger	67
Assessing left ventricular systolic function: from ejection fraction to strain analysis	67
Predicted benefit of an implantable cardioverter-defibrillator: the MADIT-ICD benefit score	67
Acute mental stress drives vascular inflammation and promotes plaque destabilization in mouse atherosclerosis	66
Ticagrelor monotherapy in patients at high bleeding risk undergoing percutaneous coronary intervention: TWILIGHT-HBR	66
Phenotypic clustering of dilated cardiomyopathy patients highlights important pathophysiological differences	66
Atrial fibrillation and kidney function: a bidirectional Mendelian randomization study	66
Renal denervation in the management of hypertension in adults. A clinical consensus statement of the ESC Council on Hypertension and the European Association of Percutaneous Cardiovascular Interventio	65
Prediction of ventricular arrhythmia in phospholamban p.Arg14del mutation carriers–reaching the frontiers of individual risk prediction	65
Brugada syndrome genetics is associated with phenotype severity	65
Vigorous physical activity, incident heart disease, and cancer: how little is enough?	65
Transition to adulthood and transfer to adult care of adolescents with congenital heart disease: a global consensus statement of the ESC Association of Cardiovascular Nursing and Allied Professions (A	64
Restrictive cardiomyopathy: definition and diagnosis	64
Elevated remnant cholesterol, plasma triglycerides, and cardiovascular and non-cardiovascular mortality	64
A worldwide survey on incidence, management, and prognosis of oesophageal fistula formation following atrial fibrillation catheter ablation: the POTTER-AF study	64
Fractional flow reserve versus angiography-guided strategy in acute myocardial infarction with multivessel disease: a randomized trial	63
The struggle towards a Universal Definition of Heart Failure—how to proceed?	63
The effect of intravenous ferric carboxymaltose on cardiac reverse remodelling following cardiac resynchronization therapy—the IRON-CRT trial	63
Dapagliflozin for heart failure according to body mass index: the DELIVER trial	63
Longitudinal strain is an independent predictor of survival and response to therapy in patients with systemic AL amyloidosis	63
Vegetarians, fish, poultry, and meat-eaters: who has higher risk of cardiovascular disease incidence and mortality? A prospective study from UK Biobank	63
PCSK9 deficiency rewires heart metabolism and drives heart failure with preserved ejection fraction	62
Targeted proteomics improves cardiovascular risk prediction in secondary prevention	62
Five-year outcomes after state-of-the-art percutaneous coronary revascularization in patients with de novo three-vessel disease: final results of the SYNTAX II study	62
Artificial intelligence in the diagnosis and management of arrhythmias	61
Modifiable risk factors associated with cardiovascular disease and mortality in China: a PURE substudy	61
Sleep arousal burden is associated with long-term all-cause and cardiovascular mortality in 8001 community-dwelling older men and women	61
Standardized exercise training is feasible, safe, and effective in pulmonary arterial and chronic thromboembolic pulmonary hypertension: results from a large European multicentre randomized controlled	60
Short-coupled ventricular fibrillation represents a distinct phenotype among latent causes of unexplained cardiac arrest: a report from the CASPER registry	60
Estimation of recurrent atherosclerotic cardiovascular event risk in patients with established cardiovascular disease: the updated SMART2 algorithm	60
Association of β-blocker use with survival and pulmonary function in patients with chronic obstructive pulmonary and cardiovascular disease: a systematic review and meta-analysis	60
Evolution of antithrombotic therapy in patients undergoing percutaneous coronary intervention: a 40-year journey	60
Brugada syndrome and reduced right ventricular outflow tract conduction reserve: a final common pathway?	60
Hypertension management in patients with cardiovascular comorbidities	59
Trends in survival after cardiac arrest: a Swedish nationwide study over 30 years	59
A possible explanation for the contrasting results of REDUCE-IT vs. STRENGTH: cohort study mimicking trial designs	59
Cardiac sarcoidosis: phenotypes, diagnosis, treatment, and prognosis	58
Association of the combined effects of air pollution and changes in physical activity with cardiovascular disease in young adults	58
Corrigendum to: 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary s	58
Exercise benefits in cardiovascular diseases: from mechanisms to clinical implementation	57
Accelerated and personalized therapy for heart failure with reduced ejection fraction	57
Silent brain infarcts impact on cognitive function in atrial fibrillation	57
Uric acid and sodium-glucose cotransporter-2 inhibition with empagliflozin in heart failure with reduced ejection fraction: the EMPEROR-reduced trial	57
Automated external defibrillators delivered by drones to patients with suspected out-of-hospital cardiac arrest	56
The association of amputations and peripheral artery disease in patients with type 2 diabetes mellitus receiving sodium-glucose cotransporter type-2 inhibitors: real-world study	56
Two-year outcome after implantation of a full magnetically levitated left ventricular assist device: results from the ELEVATE Registry	56
Prognostic value of stress echocardiography assessed by the ABCDE protocol	56
Robustness and relevance of predictive score in sudden cardiac death for patients with Brugada syndrome	55
Molecular imaging-guided repair after acute myocardial infarction by targeting the chemokine receptor CXCR4	55
Blood pressure lowering and prevention of dementia: an individual patient data meta-analysis	55
Integrated care for optimizing the management of stroke and associated heart disease: a position paper of the European Society of Cardiology Council on Stroke	55
Chronic obstructive pulmonary disease and atrial fibrillation: an interdisciplinary perspective	54
Tilt testing remains a valuable asset	54
SGLT2 inhibitors: the statins of the 21st century	54
Alpha-protein kinase 3 (ALPK3) truncating variants are a cause of autosomal dominant hypertrophic cardiomyopathy	54
Coronary flow velocity reserve predicts adverse prognosis in women with angina and no obstructive coronary artery disease: results from the iPOWER study	54
Sodium intake, life expectancy, and all-cause mortality	54
Predictors of mortality in thrombotic thrombocytopenia after adenoviral COVID-19 vaccination: the FAPIC score	54
Extracellular vesicles from immortalized cardiosphere-derived cells attenuate arrhythmogenic cardiomyopathy in desmoglein-2 mutant mice	54
Smoking cessation, but not reduction, reduces cardiovascular disease incidence	54
Ultra-processed food intake and all-cause and cause-specific mortality in individuals with cardiovascular disease: the Moli-sani Study	54
Macrophage NFATc3 prevents foam cell formation and atherosclerosis: evidence and mechanisms	53
Genome-wide association analysis in dilated cardiomyopathy reveals two new players in systolic heart failure on chromosomes 3p25.1 and 22q11.23	53
A circular RNA derived from the insulin receptor locus protects against doxorubicin-induced cardiotoxicity	53
Attaining sinus rhythm mediates improved outcome with early rhythm control therapy of atrial fibrillation: the EAST-AFNET 4 trial	53
Cardiovascular magnetic resonance in light-chain amyloidosis to guide treatment	53
Cardiovascular disease, mortality, and their associations with modifiable risk factors in a multi-national South Asia cohort: a PURE substudy	53
Prevention and treatment of pulmonary congestion in patients undergoing venoarterial extracorporeal membrane oxygenation for cardiogenic shock	53
Lipoprotein(a) is associated with the onset but not the progression of aortic valve calcification	53
Anticancer drug-induced life-threatening ventricular arrhythmias: a World Health Organization pharmacovigilance study	52
Subcutaneous implantable cardioverter-defibrillators: long-term results of the EFFORTLESS study	52
Nomenclature for kidney function and disease—executive summary and glossary from a Kidney Disease: Improving Global Outcomes (KDIGO) consensus conference	52
Accelerometer-derived physical activity and risk of atrial fibrillation	52
Effect of inclisiran on lipids in primary prevention: the ORION-11 trial	52
Long-term follow-up after ultrathin vs. conventional 2nd-generation drug-eluting stents: a systematic review and meta-analysis of randomized controlled trials	52
Impact of sex on the management and outcome of aortic stenosis patients	52
Percutaneous coronary intervention in patients with cancer and readmissions within 90 days for acute myocardial infarction and bleeding in the USA	51
Which patients with aortic stenosis should be referred to surgery rather than transcatheter aortic valve implantation?	51
Silent brain infarcts and early cognitive outcomes after transcatheter aortic valve implantation: a systematic review and meta-analysis	51
The ‘Ten Commandments’ of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure	51
Reduction of environmental pollutants for prevention of cardiovascular disease: it’s time to act	51
Atrial septal defect in adulthood: a new paradigm for congenital heart disease	50
All-cause mortality and location of death in patients with established cardiovascular disease before, during, and after the COVID-19 lockdown: a Danish Nationwide Cohort Study	50
Cardiotoxicity from chimeric antigen receptor-T cell therapy for advanced malignancies	50
Immune complexes, innate immunity, and NETosis in ChAdOx1 vaccine-induced thrombocytopenia	50
Importance of genotype for risk stratification in arrhythmogenic right ventricular cardiomyopathy using the 2019 ARVC risk calculator	50